An increased level of investment in sales, marketing and R&D will impact BSM Technologies’ (BSM Technologies Stock Quote, Chart, News: TSXV:GPS) EBITDA margins, says Paradigm Capital analyst Gabriel Leung.
In a research update to clients yesterday, Leung maintained his “Buy” rating on BSM, but lowered his one-year target on the stock from $3.00 to $2.75. The analyst’s new price target implied a return of 67% at the time of publication.
Leung says that while he is maintaining his fiscal 2015 revenue forecast of $34.6-million, he is lowering his expectation on EBITDA margins from 22.8% to 15.5%. He says this actions reflects his view that “the company will likely increase investments in key operating areas, such as sales and marketing and R&D”.
The analyst says he remains bullish on BSM because of a growing backlog of enterprise customers, its strong vertical focus, and what he says are initial signs of cross-selling activity. He notes that the telematics space is a particularly acquisitive one and thinks BSM is a potential takeout target.
In BSM’s upcoming fourth quarter, Leung expects the company will generate EBITDA of $946,000 on revenue of $7.4-million, with 12.8% EBITDA margins.
At press time, shares of BSM Technologies were up 1.2% to $1.70.
Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]
National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]
RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]
Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]
Roth Capital Partners analyst Craig Irwin says VersaBank (VersaBank Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) is nearing a potential… [Read More]
Roth Capital Partners analyst Max Masucci says Rapid Micro Biosystems (Rapid Micro Biosystems Stock Quote, Chart, News, Analysts, Financials NASDAQ:RPID)… [Read More]